• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Reflections on cancer treatment and the federal agency regulations.

作者信息

Saenger E L, Kereiakes J G

出版信息

Radiology. 1980 Dec;137(3):865-6. doi: 10.1148/radiology.137.3.7444073.

DOI:10.1148/radiology.137.3.7444073
PMID:7444073
Abstract

Medical licenses issued by the Nuclear Regulatory Commission contain the restriction that patients who are being treated with 131I should not be discharged from the hospital if the body burden is greater than 30 mCi (1,110 MB1). It is argued that there are no sound data supporting the theory that a patient receiving more than 30 mCi (1,110 MB1) of 131I is dangerous to others. This limitation may result in the use of lower, less effective doses of 131I, so that expensive, unnecessary hospitalization can be avoided. The need for adequate radiation safety programs that will advise patients and their families of the necessary precautions following therapy with 131I is discussed.

摘要

相似文献

1
Reflections on cancer treatment and the federal agency regulations.
Radiology. 1980 Dec;137(3):865-6. doi: 10.1148/radiology.137.3.7444073.
2
Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
J Nucl Med. 2000 Nov;41(11):1868-75.
3
NRC absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary.131I治疗患者家庭成员的NRC吸收剂量重建:案例研究与评论
J Nucl Med. 2004 Apr;45(4):13N-6N, 37N.
4
Applying Nuclear Regulatory Commission guidelines to the release of patients treated with sodium iodine-131.将核管理委员会的指导方针应用于接受碘 - 131钠治疗患者的释放。
J Nucl Med Technol. 2000 Dec;28(4):275-9.
5
Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with 131I.被许可方过度依赖美国核管理委员会(NRC)关于接受131I治疗患者出院指导中的保守做法。
Health Phys. 2007 Dec;93(6):667-77. doi: 10.1097/01.HP.0000270300.34270.44.
6
Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.131I 放射性碘治疗甲状腺疾病患者的辐射安全:美国甲状腺协会的实践建议。
Thyroid. 2011 Apr;21(4):335-46. doi: 10.1089/thy.2010.0403. Epub 2011 Mar 18.
7
The AEC/NRC 30 mCi rule: regulatory origins and clinical consequences for 131I remnant ablative doses.美国核管理委员会(NRC)的30毫居里(mCi)规则:131碘残留消融剂量的监管起源及临床后果
Thyroid. 2014 Nov;24(11):1625-35. doi: 10.1089/thy.2013.0714. Epub 2014 Aug 20.
8
Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.甲状腺癌的治疗:重点关注高剂量¹³¹I门诊治疗。
J Nucl Med Technol. 2002 Dec;30(4):165-71; quiz 172-3.
9
Outpatient therapeutic 131I for thyroid cancer.甲状腺癌的门诊治疗性131I
J Nucl Med Technol. 2005 Mar;33(1):28-30.
10
Radiation safety precautions in the management of the hospitalized (131)I therapy patient.
J Nucl Med Technol. 2001 Jun;29(2):61-6; test 74-5.